Medtronic plc added a second U.S. FDA pulsed field ablation (PFA) device approval to its scorecard with the agency’s ...

If the maximum fair prices (MFPs) the U.S. CMS announced after the first round of drug price negotiations are any indication, advocates of the government price setting may be settling for short-term ...

Privately held Dyno Therapeutics Inc. has added another notch to its adeno-associated virus (AAV) vectors development ...

Wee1 and PKMYT1 are two kinases involved in DNA damage repair. The former is located in the nucleus and the latter in the endoplasmic reticulum. Several selective inhibitors of Wee1 or PKMYT1 have ...

Despite an outcome that TD Cowen analyst Tyler Van Buren called ”fantastic,” shares of Tyra Biosciences Inc. (NASDAQ:TYRA) closed Oct. 25 at $21.93, down $6.68, or 23%, as Wall Street digested new ...

Delta-like ligand 3 (DLL3) is a highly relevant target for radiopharmaceutical therapy due to its expression in more than 85% of tumors of patients with small-cell lung cancer.

The Medical Information Working Group again took up a question regarding U.S. FDA-regulated speech, citing the agency’s new misinformation draft guidance as an example of a piecemeal approach to ...

Children with autism spectrum disorder (ASD) often must wait years before they get a diagnosis, and that wait time can result in missed opportunities for changing behaviors associated with autism.

Aevisbio Inc. and the Korea Research Institute of Chemical Technology have jointly developed new compounds targeting protein cereblon (CRBN) reported to be useful for the treatment of cancer.

Bayer AG has entered into an exclusive licensing agreement with Dewpoint Therapeutics Inc. for a heart disease program to treat dilated cardiomyopathy (DCM) patients characterized by specific ...

Cancer Research UK and Kisoji Biotechnology Inc. have signed an agreement to bring Kisoji's naked anti-TROP2 antibody, KJ-103, into a first-in-human trial. KJ-103 is a single domain antibody that ...

Beijing Primegene Therapeutics Co. Ltd. has patented macrocyclic compounds acting as non-receptor tyrosine-protein kinase TYK2 (JH2 domain) allosteric inhibitors reported to be useful for the ...